Vir Biotechnology, Inc. Stock News

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Maria

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.

Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 202

Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk

Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.

The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #JPM2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J

Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential gian

Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, bu

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer M